Brought to you by 
T2 Biosystems brings in $15mm through its Series C round
28 May 2010
Executive Summary
T2 Biosystems Inc. (rapid molecular testing using nanotechnology and miniaturized magnetic resonance) has raised $15mm through its Series C financing led by first-time backer Physic Ventures, which adds a board member. Other new investors Arcus Ventures, RA Capital, Camros Capital, and WS Investments were joined by returning shareholders Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, and Partners Healthcare. The company will use the money for ongoing development and the eventual commercialization of its next-generation diagnostic platform for use in a decentralized setting. T2 Biosystems' October 2008 Series B round generated $10.8mm.
Deal Industry
- In Vitro Diagnostics
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- MRI, NMR
-
Diagnostic Imaging Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Urine-based Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
T2 Biosystems brings in $15mm through its Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice